Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) from a boosted protease inhibitor-based regimen

被引：0
|
作者：
Rockstroh, J. [1 ]
Molina, J. M. [2 ]
Post, F. [3 ]
Fox, J. [4 ]
Koenig, E. [5 ]
Daar, E. S. [6 ]
Ruane, P. [7 ]
Crofoot, G. [8 ]
Oguchi, G. [9 ]
Creticos, C. [10 ]
Liu, A. [11 ]
Andreatta, K. [11 ]
Graham, H. [11 ]
Brainard, D. [11 ]
Martin, H. [11 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
[2] Hop St Louis, Paris, France
[3] Kings Coll Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Inst Dominicano Estudios Virol IDEV, Santo Domingo, Dominican Rep
[6] Harbor UCLA Med Ctr, Lundquist Inst, Torrance, CA 90509 USA
[7] Ruane Clin Res Grp Inc, Los Angeles, CA USA
[8] Crofoot Res Ctr, Houston, TX USA
[9] Midland Florida Clin Res Ctr, Deland, FL USA
[10] Howard Brown Hlth Ctr, Chicago, IL USA
[11] Gilead Sci Inc, Foster City, CA USA
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
O005
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [21] Impact of food on the bioavailability of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (DCFTAF), the first protease inhibitor-based complete HIV-1 regimen
    Crauwels, Herta
    Baugh, Bryan
    Van Landuyt, Erika
    Vanveggel, Simon
    Hijzen, Anja
    Opsomer, Magda
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [22] Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)
    Iwuji, Collins
    Waters, Laura
    Milinkovic, Ana
    Orkin, Chloe
    Fox, Julie
    Post, Frank
    Perry, Nicky
    Bruce, Chloe
    Dailey, Natalie
    To, Ye
    Bremner, Stephen
    Churchill, Duncan
    Geretti, Anna Maria
    VIROLOGY JOURNAL, 2025, 22 (01)
  • [23] Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study
    Gallien, Sebastien
    Assoumou, Lambert
    Dantal, Jacques
    Hulin, Anne
    Benalycherif, Aida
    Ben Rayana, Raida
    Tobbal, Yasmine
    Matignon, Marie
    Melica, Giovanna
    Allavena, Clotilde
    Stehle, Thomas
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 286 - 287
  • [24] Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
    Santos, J. R.
    Cozzi-Lepri, A.
    Phillips, A.
    De Wit, S.
    Pedersen, C.
    Reiss, P.
    Blaxhult, A.
    Lazzarin, A.
    Sluzhynska, M.
    Orkin, C.
    Duvivier, C.
    Bogner, J.
    Gargalianos-Kakolyris, P.
    Schmid, P.
    Hassoun, G.
    Khromova, I.
    Beniowski, M.
    Hadziosmanovic, V.
    Sedlacek, D.
    Paredes, R.
    Lundgren, J. D.
    HIV MEDICINE, 2018, 19 (05) : 324 - 338
  • [25] Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to <12 years)
    Cotton, M.
    Liberty, A.
    Rodriguez, C. A.
    Chokephaibulkit, K.
    Kosalaraksa, P.
    Hellstrom, E.
    Natukunda, E.
    Wong, P.
    Majeed, S. R.
    Quirk, E.
    Graham, H.
    Pikora, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 38 - 39
  • [26] Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
    Sax, Paul E.
    Arribas, Jose R.
    Orkin, Chloe
    Lazzarin, Adriano
    Pozniak, Anton
    DeJesus, Edwin
    Maggiolo, Franco
    Stellbrink, Hans-Joergen
    Yazdanpanah, Yazdan
    Acosta, Rima
    Huang, Hailin
    Hindman, Jason T.
    Martin, Hal
    Baeten, Jared M.
    Wohl, David
    ECLINICALMEDICINE, 2023, 59
  • [27] Switching to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance: a phase IV randomised, open-label pilot study (PIBIK study)
    Iwuji, C.
    Waters, L.
    Milinkovic, A.
    Orkin, C.
    Perry, N.
    Dailey, N.
    To, Y.
    Bremner, S.
    Geretti, A.
    Churchill, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 89 - 90
  • [28] Switching to bictegravir/ emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance - A phase IV randomized, open-label pilot study (PIBIK study)
    Iwuji, C.
    Waters, L.
    Milinkovic, A.
    Orkin, C.
    Fox, J.
    Post, F.
    Perry, N.
    Bruce, C.
    Dailey, N.
    To, Y.
    Bremner, S.
    Geretti, A. M.
    Churchill, D.
    HIV MEDICINE, 2023, 24 : 681 - 683
  • [29] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV aged 65 years or older: W24 results of the BICOLDER study - IMEA 057
    Allavena, C.
    Joly, V.
    Assoumou, L.
    Isernia, V.
    Ajana, F.
    Neau, D.
    Descamps, D.
    Charpentier, C.
    Benalycherif, A.
    Metivier, E.
    Peytavin, G.
    Phung, B.
    Landman, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 47 - 47
  • [30] Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
    Monforte, Antonella d'Arminio
    Tavelli, Alessandro
    Di Biagio, Antonio
    Sarmati, Loredana
    Marchetti, Giulia C.
    Bai, Francesca
    Cingolani, Antonella
    Roldan, Eugenio Quiros
    Mussini, Cristina
    Lichtner, Miriam
    Vergori, Alessandra
    Piconi, Stefania
    Orofino, Giancarlo
    Fusco, Francesco Maria
    Bandera, Alessandra
    Nozza, Silvia
    Castagna, Antonella
    Antinori, Andrea
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (06) : 1279 - 1288
12345